Improving compliance to Parkinsonism’s pharmacotherapy amongst patients attending a Movement Disorders Clinic (MDC)
Objective: To improve patients’ compliance with Parkinsonism's pharmacotherapy to achieve more accurate clinical assessment in an outpatient setting. Background: Patients with Parkinsonism are encouraged to…SYN120 (a Dual 5-HT6/5-HT2A Antagonist) Study to Evaluate Safety, Tolerability and Efficacy in Parkinson’s Disease Dementia (SYNAPSE): Phase 2a Study Results
Objective: To evaluate the safety and preliminary efficacy of SYN120 in patients with Parkinson's disease dementia (PDD). Background: SYN120 is an antagonist of serotonin receptors…Exploring The Role of a Prescribing Pharmacist in the Management of Parkinson’s Disease
Objective: Aims/Objectives A review to explore the role of a pharmacist NMP within the neurology PD multidisciplinary team during a six month period between 1st…The anti-dyskinetic effect of the clinically-available 5-HT3 receptor antagonist granisetron in the 6-OHDA-lesioned rat model of Parkinson’s disease
Objective: To determine the effect of the serotonin 3 (5-HT3) receptor antagonist granisetron, a clinically-available anti-emetic, on L-3,4-dihydroxyphenylalanine (L-DOPA)-induced dyskinesia. Background: Dopamine replacement with L-DOPA…Costs and outcomes for Parkinson’s disease patients who have their management adjusted by Personal KinetiGraph (PKG)
Objective: To quantify the potential cost savings and quality adjusted life years (QALYs) gained for people with Parkinson’s disease in Australia whose oral therapy was…7 years later, are the Tomlinson’s levodopa dose equivalencies proposed consensual?
Objective: (i) To collect all the levodopa equivalent doses (LED) formulae and references used in clinical trials in Parkinson’s disease (PD) since the publication of…Personal KinetiGraph™ Movement Recording System: An Assessment of Utility in a Movement Disorder Clinic
Objective: The objective of this open-label study was to evaluate the clinical utility of the Personal KinetiGraph™ (PKG) Movement Recording System in the care of…Weight variation in Parkinson’s disease patients treated with levodopa-carbidopa intestinal gel infusion
Objective: To compare weight variations between three cohorts of patients with advanced Parkinson’s disease (PD): patients during their first year of treatment either with levodopa-carbidopa…Therapeutic Drug Monitoring and Pharmacogenetic Tests as Tools in Pharmacovigilance of Anti Parkinson’s Therapy
Objective: Parkinson's disease (PD) is the second most prevalent neurodegenerative disease worldwide, affecting more than 7 million people worldwide. However, treatment outcome in many patients…Ondansetron, a highly-selective 5-HT3 receptor antagonist, alleviates L-DOPA-induced dyskinesia in the 6-OHDA-lesioned rat model of Parkinson’s disease
Objective: To determine the effectiveness of selective serotonin 3 (5-HT3) receptor blockade at reducing the severity of established, and preventing the development of, dyskinesia. Background:…
- « Previous Page
- 1
- …
- 28
- 29
- 30
- 31
- 32
- …
- 36
- Next Page »